News

Otsuka Pharmaceutical Development & Commercialization, Inc., together with Otsuka Pharmaceutical Co., Ltd., has reached a key regulatory milestone after the U.S. Food and Drug…
Read More...

Simcere Pharmaceutical Group Ltd. and Boehringer Ingelheim have entered into a global license and collaboration agreement to develop SIM0709, a pre-clinical bispecific antibody designed…
Read More...

Insilico Medicine and Qilu Pharmaceutical Group have entered into a strategic partnership aimed at accelerating the discovery and development of new therapies for cardiometabolic…
Read More...

Mirum Pharmaceuticals, Inc. has completed its acquisition of Bluejay Therapeutics, a privately held biotechnology company focused on viral and liver diseases, marking a significant step…
Read More...

Eisai Co., Ltd. and Biogen Inc. have announced a key regulatory milestone for their Alzheimer’s disease therapy lecanemab-irmb, marketed in the United States as LEQEMBI®. The U.S. Food…
Read More...

WuXi Biologics and HanchorBio Inc. have announced a strategic collaboration aimed at accelerating the development and manufacturing of multiple next-generation bi- and multi-functional…
Read More...

Corxel Pharmaceuticals Limited (CORXEL), a clinical-stage biopharmaceutical company focused on cardiometabolic diseases, has announced the successful completion of its Series D1…
Read More...

Janux Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on next-generation immunotherapies, has entered into a collaboration and exclusive worldwide license…
Read More...

China’s National Medical Products Administration (NMPA) has approved ENHERTU® (trastuzumab deruxtecan) for the treatment of adult patients with locally advanced or metastatic…
Read More...

Insilico Medicine and Hygtia Therapeutics have entered into an exclusive global license and co-development agreement to advance ISM8969, an investigational NLRP3 inhibitor designed for…
Read More...

Wugen has received a major regulatory endorsement from the U.S. Food and Drug Administration, which has granted Breakthrough Therapy Designation to its investigational CAR-T cell…
Read More...

Charles River Laboratories International and Gazi University Faculty of Medicine have entered into a strategic collaboration aimed at advancing gene therapy research for rare genetic…
Read More...

NEOK Bio has taken a key step toward clinical development after the U.S. Food and Drug Administration approved its Investigational New Drug application for NEOK001, clearing the way for…
Read More...

Opna Bio, a clinical-stage biopharmaceutical company focused on developing novel cancer therapies, has received a key regulatory boost for its myelofibrosis program. The U.S. Food and…
Read More...

Novo Nordisk and Aspect Biosystems have announced the expansion of their strategic partnership, entering a new phase focused on developing advanced cellular medicines for diabetes that…
Read More...

Bristol Myers Squibb (BMS) has entered into a strategic collaboration with Microsoft to accelerate the early detection of lung cancer by integrating advanced artificial intelligence…
Read More...

GSK plc and Japan-based pharmaceutical company Shionogi & Co., Ltd. have reached an agreement, alongside Pfizer Inc., to reshape the ownership structure of ViiV Healthcare, the…
Read More...

AstraZeneca has agreed to acquire AbelZeta Pharma’s remaining stake in the China development and commercialization rights to C-CAR031, consolidating full global control of the…
Read More...

iRegene Therapeutics has reached a major regulatory milestone with its lead program for Parkinson’s disease, as the U.S. Food and Drug Administration granted Regenerative Medicine…
Read More...

Novartis has received a significant regulatory boost for its autoimmune disease pipeline after the U.S. Food and Drug Administration granted Breakthrough Therapy designation to…
Read More...